MARKET

INAB

INAB

In8Bio, Inc.
NASDAQ
1.890
-0.020
-1.05%
After Hours: 1.870 -0.02 -1.06% 16:10 03/13 EDT
OPEN
1.900
PREV CLOSE
1.910
HIGH
1.990
LOW
1.820
VOLUME
61.13K
TURNOVER
--
52 WEEK HIGH
7.86
52 WEEK LOW
1.170
MARKET CAP
18.46M
P/E (TTM)
-0.4253
1D
5D
1M
3M
1Y
5Y
1D
IN8bio Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Reiterates Buy on IN8bio, Maintains $6 Price Target
Benzinga · 1d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Korro Bio (KRRO), IN8bio (INAB) and Aveanna Healthcare Holdings (AVAH)
TipRanks · 1d ago
Analysts Are Bullish on Top Healthcare Stocks: HeartBeam (BEAT), IN8bio (INAB)
TipRanks · 2d ago
IN8bio Q4 net loss narrows, cash position more than doubles
Reuters · 2d ago
*IN8bio Sees Guidance From FDA on Potential Regulatory Pathway by 2H
Dow Jones · 2d ago
*IN8bio: Initial Preclinical Animal Data and Additional IND-enabling Data for INB-619 Expected in 2H >INAB
Dow Jones · 2d ago
*IN8bio 4Q Loss $4.9M >INAB
Dow Jones · 2d ago
More
About INAB
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.

Webull offers IN8bio Inc stock information, including NASDAQ: INAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INAB stock methods without spending real money on the virtual paper trading platform.